Incyte Corp. — Sponsor Intelligence | 59 EU Trials

Filter these 59 trials by condition, phase, country and more.

Open in Search →

59 Registered trials

22 Recruiting

34 Completed trials

21 Countries active

49 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase III: 28 Phase II/III: 1 Phase II: 16 Phase I/II: 4 Phase I: 6 Phase I (Other): 4

Oversight events:

4 temporary halts across 1 trial

View oversight register →

100%

34 of 34 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Vitiligo 5 Chronic graft versus host disease 5 Myelofibrosis 3 Non-small cell lung cancer 3 Malignant melanoma stage IV 3 Non-small cell lung cancer stage IV 3 Diffuse large B-cell lymphoma 3 Metastatic malignant melanoma 3 Non-small cell lung cancer metastatic 3 Hepatocellular carcinoma 2 Ovarian cancer 2 Myeloproliferative neoplasm 2

Top IMPs

RUXOLITINIB 12 4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]-2,5-DIFLUORO-N-[(2S)-1,1,1-TRIFLUOROPROPAN-2-YL]BENZAMIDE 7 TAFASITAMAB 7 POVORCITINIB 5 AXATILIMAB 4 INCB099280 4 RETIFANLIMAB 4 LENALIDOMIDE 3 PEMIGATINIB 3 8-ETHOXY-N-((3R,4S)-3-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL)-7-(1H-PYRAZOL-4-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE 2 CARBOPLATIN 2 CISPLATIN 2

All trials — page 2

59 total

A study evaluating the safety and efficacy of ponatinib for the treatment of recurrent or refractory leukemias or solid tumors in children Recruiting

2023-509699-41-00 Phase I/II 6 countries PONATINIB
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended

2024-511881-35-00 Phase III 5 countries 4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]…
INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru… Ended

2022-502168-19-00 Phase II 4 countries AXATILIMAB; RUXOLITINIB
Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended

2023-507204-31-00 Phase III 12 countries 4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]…
Selective Treatment of Oral Povorcitinib in Vitiligo Study 1 (STOP-V1) Ended

2023-505782-86-00 Phase III 6 countries POVORCITINIB
Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended

2023-506011-18-00 Phase III 6 countries POVORCITINIB
A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Ended

2023-505579-53-00 Phase III 10 countries LENALIDOMIDE; TAFASITAMAB
A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with … Ended

2023-507993-42-00 Phase I/II 5 countries LENALIDOMIDE; TAFASITAMAB
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants Wit… Ended

2023-503624-83-00 Phase I/II 2 countries
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended

2023-504684-16-00 Phase III 16 countries LENALIDOMIDE; RITUXIMAB; TAFASITAMAB
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Phase III 11 countries TAFASITAMAB
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance… Ended

2022-502600-79-00 Phase II 4 countries HUMAN IGG1K MONOCLONAL ANTIBODY AGAINST TIM-3; PEMIGATINIB; RETIFANLIMAB; TUPARS…
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation Halted

2023-507091-47-00 Phase I 4 countries
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Modera… Ended

2023-505433-27-00 Phase III 9 countries RUXOLITINIB
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended

2023-503223-26-00 Phase I/II 3 countries ADAGRASIB; INCB099280
A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended

2022-502461-23-00 Phase III 8 countries RUXOLITINIB
A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended

2022-502716-37-00 Phase II 3 countries INCB099280
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended

2022-503062-72-00 Phase II 2 countries POVORCITINIB
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo Ended

2023-503737-22-00 Phase II 1 country RUXOLITINIB
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended

2022-502476-23-00 Phase II 7 countries INCB099280
A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label E… Ended

2022-502827-23-00 Phase II 2 countries RUXOLITINIB
A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended

2022-501621-20-00 Phase III 7 countries RUXOLITINIB
INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Stu… Ended

2022-501661-47-00 Phase II 6 countries ITACITINIB
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Phase III 9 countries 4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]…

Showing 25–48 of 59 trials

← All sponsors A–Z